Background: The focus of the present Letter is on the large and seemingly fertile body of work captured under the umbrella of 'patient stratification'.
Objectives: I identify and explain a fundamental methodological flaw underlying the manner in which the development of an increasingly large number of new stratification strategies is approached.
Design: I show an inherent conflict between the assumptions made, and the very purpose of stratification and its application in practice.
Methods: I analyse the methodological underpinnings of stratification as presently done and draw parallels with conceptually similarly flawed precedents which are now widely recognized.
Results: The highlighted flaw is shown to undermine the overarching ultimate goal of improved patient outcomes by undue fixation on an ill-founded proxy.
Conclusion: I issue a call for a re-think of the problem and the processes leading to the adoption of new stratification strategies in the clinic.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186568 | PMC |
| http://dx.doi.org/10.1177/11772719231174746 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Analysis of Percutaneous Nephrolithotomy (PCNL) Performed at the Institute of Kidney Disease, Pakistan: Stone Clearance and Complications.
Cureus
December 2024
Department of Cardiovascular Medicine, Khyber Medical Institute of Medical Sciences, Kohat, PAK.
Background: Percutaneous nephrolithotomy (PCNL) is the preferred treatment for large renal stones, yet variability in outcomes arises from patient-specific factors and institutional practices. Understanding complications and predictors of success is essential to improving procedural efficacy.
Objective: This study aimed to evaluate stone clearance rates, complications classified using the Clavien-Dindo system, and predictors of PCNL outcomes, with a focus on improving lower calyx stone clearance.
Association of Surgical Complications With Resource Utilization in Adult Congenital Cardiac Surgery.
Ann Thorac Surg Short Rep
September 2023
Cardiovascular Outcomes Research Laboratories (CORELAB), David Geffen School of Medicine at UCLA, Los Angeles, California.
Background: As patients with congenital heart disease are increasingly surviving well into adulthood, the morbidity, mortality, and resource utilization of adult congenital cardiac operations are of increasing interest. Therefore, we evaluated factors associated with perioperative morbidity and outcomes in adults undergoing congenital operations.
Methods: The Nationwide Readmissions Database was tabulated for all adults (≥18 years old) with congenital heart disease between 2010 and 2017.
Risk Factors for Extraocular Relapse in Retinoblastoma.
Semin Ophthalmol
January 2025
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Barcelona, Spain.
Background: Metastatic retinoblastoma remains a significant challenge in pediatric oncology, with stark disparities in survival outcomes between high-income countries (HICs) and low-income countries (LICs). Delayed diagnosis and treatment, driven by socioeconomic factors and limitations in healthcare systems, contribute to poorer outcomes in LICs. Histopathological characteristics, including high-risk pathology factors (HRPFs) and the extent of ocular tumor invasion, are critical for predicting metastatic risk and guiding treatment strategies.
View Article and Find Full Text PDFEfficacy of geneguided preemptive therapy for prevention of relapse in acute myeloid leukemia after transplantation and its optimal intervention threshold.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
July 2024
Department of Hematology, Xiangya Hospital, Central South University, Changsha 410008.
Objectives: Monitoring minimal residual disease (MRD) and timely intervention are effective strategies for preventing relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult acute myeloid leukemia (AML). The gene, a pan-leukemia marker, can be used as an indicator for MRD monitoring in AML patients. Currently, there is no unified standard for the intervention timing or treatment threshold based on gene detection after transplantation.
View Article and Find Full Text PDFAdvancing Drug Development in Myelodysplastic Syndromes.
Blood Adv
December 2024
U.S. Food and Drug Administration, Silver Spring, Maryland, United States.
Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous stem cell malignancies characterized by poor prognosis and no curative therapies outside of allogeneic hematopoietic stem cell transplantation. Despite some recent approvals by the United States Food and Drug Administration (FDA), (e.g.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!